UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of The Securities Exchange Act of 1934

 

Date of Report (Date of Earliest Event Reported):   August 11 , 2016

 

 

Voyager Therapeutics, Inc.

(Exact name of registrant as specified in its charter)

 

 

 

 

 

 

 

DELAWARE

 

001-37625

 

46-3003182

(State or other jurisdiction
of incorporation)

 

(Commission
File Number)

 

(I.R.S. Employer
Identification No.)

 

 

 

 

75 Sidney Street
Cambridge, Massachusetts

 

02139

(Address of principal executive offices)

 

(Zip Code)

 

Registrant’s telephone number, including area code (857) 259-5340

 

Not Applicable

(Former name or former address, if changed since last report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 

 

Item 2.02. Results of Operations and Financial Condition.

On August 11 , 201 6 ,   V oyager Therapeutics, Inc. (the “Company”) announced financial results for the quarter   ended June  3 0 , 2016 . The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

 

The information in this Form 8-K (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such a filing.

 

Item 9.01. Financial Statements and Exhibits

(d)      Exhibits

 

The following exhibit relating to Item 2.02 shall be deemed to be furnished, and not filed:

 

Mar

 

 

Exhibit
No.

 

Description

 

 

 

99.1

 

Press release dated August 11 , 2016 entitled “ Voyager Therapeutics Provides Second Quarter 2016 Investor Update ”

 

 

 

 

 

2

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

ar

 

 

Date: August 11 , 2016

VOYAGER THERAPEUTICS, INC.

 

 

 

By:  

/s/ Steven M. Paul

 

 

Steven M. Paul, M.D.

 

 

Chief Executive Officer and President

 

3

 

EXHIBIT INDEX

 

 

 

 

Exhibit
No.

 

Description

 

 

 

99.1

 

Press release dated August 11 , 2016 entitled “ Voyager Therapeutics Provides Second Quarter 2016 Investor Update ”

 

 

 

 

4

Voyager Therapeutics (NASDAQ:VYGR)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Voyager Therapeutics Charts.
Voyager Therapeutics (NASDAQ:VYGR)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Voyager Therapeutics Charts.